{"id":49749,"date":"2022-10-18T15:02:56","date_gmt":"2022-10-18T13:02:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/"},"modified":"2022-10-18T15:02:56","modified_gmt":"2022-10-18T13:02:56","slug":"variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/","title":{"rendered":"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round"},"content":{"rendered":"
\n

\nKreos Capital, the leading growth debt provider in Europe and Israel, led the financing to fuel the company\u2019s growth across all markets with a focus on precision oncology<\/i>\n<\/p>\n

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, announced today a $20M debt financing transaction with Kreos Capital. These additional funds follow the Company\u2019s recent $41.5M Series C-2 equity financing announced in February 2022.\n<\/p>\n

<\/a><\/p>\n

\nVariantyx is poised to take advantage of the rapidly growing global precision medicine market with access to North America and Europe, the largest and fastest growing regions respectively for precision medicine spending.\n<\/p>\n

\nThe Variantyx proprietary whole genome platform allows healthcare providers and their patients to better understand a person\u2019s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations. The company\u2019s precision oncology solution will use multiple genomic technologies to analyze and identify the unique genetic alterations in a patient\u2019s tumor to help predict their response to various therapies, optimize management, as well as provide prognostic and clinical trials information.\n<\/p>\n

\n\u201dWe are very pleased to partner with Kreos Capital as we seek to revolutionize the precision medicine markets\u201d said Haim Neerman, CEO of Variantyx. \u201cThis additional financing provides us resources to fuel our growth and is far less dilutive to our shareholders\u201d\n<\/p>\n

\nAris Constantinides, General Partner of Kreos Capital commented, \u201cVariantyx has built a unique and advanced platform for precision medicine and its ability to process the whole genome sets it apart in the genomic diagnostics market. Our funds, which enhance the company\u2019s already strong capital position, will allow it to significantly scale up its commercial efforts.\u201d\n<\/p>\n

\nAbout Variantyx<\/b>\n<\/p>\n

\nVariantyx is a technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians and patients to better understand a person\u2019s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations.\n<\/p>\n

\nFor more information, please visit www.variantyx.com<\/a>.\n<\/p>\n

\nAbout Kreos Capital<\/b>\n<\/p>\n

\nKreos Capital is the leading growth debt provider in Europe and Israel, backing high-growth companies through every stage of their life-cycle. Kreos targets investments in all areas of the Technology and Healthcare sectors and, to date, has committed \u20ac4.2 billion in more than 700 portfolio company transactions, across 18 countries. With over \u20ac2.0 billion in current funds under management Kreos can invest between \u20ac2 million and \u20ac100 million per transaction in both public and private companies across all stages.\n<\/p>\n

\nFor more information, please visit www.kreoscapital.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEdward J. Sitar
\n
Chief Financial Officer – Variantyx
\n
617.209.2090
\n
ed.sitar@variantyx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Kreos Capital, the leading growth debt provider in Europe and Israel, led the financing to fuel the company\u2019s growth across all markets with a focus on precision oncology FRAMINGHAM, Mass.–(BUSINESS WIRE)–Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, announced today a $20M … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49749","6":"format-standard","7":"category-industry"},"yoast_head":"\nVariantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Kreos Capital, the leading growth debt provider in Europe and Israel, led the financing to fuel the company\u2019s growth across all markets with a focus on precision oncology FRAMINGHAM, Mass.–(BUSINESS WIRE)–Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, announced today a $20M ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-18T13:02:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221018005016\/en\/1602447\/21\/Variantyx_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round\",\"datePublished\":\"2022-10-18T13:02:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/\"},\"wordCount\":453,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005016\\\/en\\\/1602447\\\/21\\\/Variantyx_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/\",\"name\":\"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005016\\\/en\\\/1602447\\\/21\\\/Variantyx_logo.jpg\",\"datePublished\":\"2022-10-18T13:02:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005016\\\/en\\\/1602447\\\/21\\\/Variantyx_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221018005016\\\/en\\\/1602447\\\/21\\\/Variantyx_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/","og_locale":"en_US","og_type":"article","og_title":"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round - Pharma Trend","og_description":"Kreos Capital, the leading growth debt provider in Europe and Israel, led the financing to fuel the company\u2019s growth across all markets with a focus on precision oncology FRAMINGHAM, Mass.–(BUSINESS WIRE)–Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, announced today a $20M ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-18T13:02:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221018005016\/en\/1602447\/21\/Variantyx_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round","datePublished":"2022-10-18T13:02:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/"},"wordCount":453,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018005016\/en\/1602447\/21\/Variantyx_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/","url":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/","name":"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221018005016\/en\/1602447\/21\/Variantyx_logo.jpg","datePublished":"2022-10-18T13:02:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221018005016\/en\/1602447\/21\/Variantyx_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221018005016\/en\/1602447\/21\/Variantyx_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/variantyx-secures-additional-20m-from-kreos-capital-following-41-5m-investment-round\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Variantyx Secures Additional $20M from Kreos Capital, Following $41.5M Investment Round"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49749","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49749"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49749\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49749"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49749"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49749"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}